Sangamo Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell SGMO and other ETFs, options, and stocks.About SGMO
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases.
CEOAlexander D. Macrae
CEOAlexander D. Macrae
Employees183
Employees183
HeadquartersRichmond, California
HeadquartersRichmond, California
Founded1995
Founded1995
Employees183
Employees183
SGMO Key Statistics
Market cap156.54M
Market cap156.54M
Price-Earnings ratio-1.05
Price-Earnings ratio-1.05
Dividend yield—
Dividend yield—
Average volume11.40M
Average volume11.40M
High today$0.4916
High today$0.4916
Low today$0.4542
Low today$0.4542
Open price$0.474
Open price$0.474
Volume2.68M
Volume2.68M
52 Week high$2.84
52 Week high$2.84
52 Week low$0.3846
52 Week low$0.3846
Stock Snapshot
Sangamo Therapeutics(SGMO) stock is priced at $0.47, giving the company a market capitalization of 156.54M. It carries a P/E multiple of -1.05.
On 2025-11-28, Sangamo Therapeutics(SGMO) stock moved within a range of $0.45 to $0.49. With shares now at $0.47, the stock is trading +2.5% above its intraday low and -5.3% below the session's peak.
Trading activity shows a volume of 2.68M, compared to an average daily volume of 11.4M.
The stock's 52-week range extends from a low of $0.38 to a high of $2.84.
The stock's 52-week range extends from a low of $0.38 to a high of $2.84.
SGMO News
Simply Wall St 5d
Revenues Working Against Sangamo Therapeutics, Inc.'s Share Price Following 33% DiveSangamo Therapeutics, Inc. ( ) shares have had a horrible month, losing 33% after a relatively good period beforehand. The recent drop completes a disastrous tw...
People also own
Based on the portfolios of people who own SGMO. This list is generated using Robinhood data, and it’s not a recommendation.